Developed in Argentina with our partners Bitgenia, our ColGenBio platform will now benefit a wider oncology patient population.
Aleksandr Bedenkov and Susana Goncalves share their thoughts on the expansion of our innovative partnership with Bitgenia to support precision medicine in Latin America.
For some time now, we have been moving away from a ‘one treatment fits all’ approach to fully embrace the potential that precision medicine offers. This is one way in which we can boost treatment outcomes, by ensuring that the right patients can receive the right medicine at the right time.
Our focus on precision medicine has been particularly evident in our A.Catalyst Network hub in Argentina, where there has been a real drive amongst healthcare professionals to accelerate the use of genomics and the latest data science technology. A precision medicine approach means treatment can be more targeted to the individual, based on more accurate diagnoses and better predictions – which, of course, gives us a greater chance of a better outcome for the patient.
In line with this movement, we’ve been working with our bioinformatics partner Bitgenia to develop our Collaborative Genomics and Biobank Platform (known as ColGenBio). Having originally focused on Argentina, we’ve now expanded this platform to support the whole of Latin America.
Opening up vital information to researchers
ColGenBio aims to improve treatment outcomes by enabling the matching of life-changing medicines with the patients most likely to benefit. It’s a software platform designed to promote and accelerate the adoption of precision medicine, by making vital clinical and genomic information available to researchers across the region.
Initially focused on oncology, the platform enables clinical laboratories and researchers to access information about anonymised samples held in laboratories across Latin American countries. This information includes the different molecular genetic data that characterise each patient. Users can organise and catalogue user-loaded samples, search for samples of interest, load genomic data associated to previously studied samples, and perform statistical analysis of available genomics and patient data.
Boosting our understanding of medicines and diseases
The ColGenBio platform provides an urgently needed source of data for researchers looking at specific biomarkers for diseases. It is designed to strengthen data collection and promotes research collaboration between laboratories, reducing duplication of efforts. Additionally, we hope that it will accelerate the adoption of approved and in-development biomarkers, and help to identify populations for new indications, as well as facilitating translational research.
Having access to these key data points will not only boost researchers’ understanding of medicines and how they work in individual patients, but will allow organisations like ourselves to learn more about diseases. This will help us to identify potential new areas of research and make better-informed decisions about how to solve the healthcare challenges of the future.
We firmly believe that ColGenBio is a significant development for precision medicine. By expanding the platform to cover all of Latin America, we are accelerating this movement and enhancing the possibilities for research across a wider population, which should ultimately give more patients access to innovative new treatments than ever before.
Being a part of the A.Catalyst Network has opened up a wealth of opportunities for precision medicine in Argentina and across Latin America. The ColGenBio platform provides an urgently needed source of genomic data for researchers looking at specific biomarkers for diseases. It promotes research collaboration between laboratories, reducing duplication of efforts. Additionally, we hope that it will accelerate the adoption of approved and in-development biomarkers, and help to identify populations for new indications, as well as facilitate translational research.
Please visit the A.Catalyst Network web page to learn more about how we are working with partners across emerging biomedical clusters to accelerate innovation, increase healthcare access and improve outcomes for society.